Impact of fracture characteristics and disease-specific complications on health-related quality of life in osteogenesis imperfecta
- 89 Downloads
Osteogenesis imperfecta (OI) is a connective tissue disease with bone fragility. Several studies have indicated that physical function in adult OI was correlated to the disease severity, but there have been no reports delineating the impact of the fracture characteristics and disease-specific complications on health-related quality of life (HRQoL). The purpose of this study is to clarify the factors impacted on HRQoL in adult OI patients. We conducted a cross-sectional study between July 2016 and March 2018 and sent a questionnaire regarding HRQoL using Short Form-36 (SF-36) to the OI patients at the age of 20 years or older who had a medical history of the investigators’ institutions. The 40 patients completely answered the SF-36. Mental component summary and role/social component summary were unremarkable. Physical component summary (PCS) was significantly associated with z-score for height, teeth abnormality, and cardiopulmonary insufficiency (partial regression coefficient, 3.04, − 9.70, and − 11.35; p, < 0.001, 0.047, and 0.025, respectively). PCS was also significantly lower in the patients who had an initial fracture before the age of 2 years than those without occurrence of fractures until 2 years old (25.80 ± 17.15 versus 44.20 ± 16.54; p = 0.002), or those who had lower extremity fractures more than five times as compared with normal populations. Physical function was decreased in OI patients who had fractures before 2 years old, especially in lower extremity. Appropriate medical managements for cardiopulmonary insufficiency are required not only to maintain physical function but also to decrease mortality.
KeywordsOsteogenesis imperfecta SF-36 Quality of life Fracture Cardiopulmonary insufficiency
This work was supported by Health Labour Sciences Research Grants, the Ministry of Health, Labour and Welfare, Japan.
Compliance with ethical standards
Conflict of interest
Each author certifies that he or she has no commercial associations that might pose a conflict of interest in connection with the submitted article.
This study was approved by institutional review board of our institutions (reference number: 2015-0412).
We obtained informed consent from all participant patients.
- 14.Tosi LL, Oetgen ME, Floor MK, Huber MB, Kennelly AM, McCarter RJ, Rak MF, Simmonds BJ, Simpson MD, Tucker CA, McKiernan FE (2015) Initial report of the osteogenesis imperfecta adult natural history initiative. Orphanet J Rare Dis 10:146. https://doi.org/10.1186/s13023-015-0362-2 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Folkestad L, Hald JD, Ersboll AK, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K (2017) Fracture rates and fracture sites in patients with osteogenesis imperfecta: a nationwide register-based cohort study. J Bone Miner Res 32:125–134. https://doi.org/10.1002/jbmr.2920 CrossRefPubMedGoogle Scholar
- 24.Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, Abrahamsen B, Brixen K (2016) Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res 31:2159–2166. https://doi.org/10.1002/jbmr.2895 CrossRefPubMedGoogle Scholar
- 31.Thiele F, Cohrs CM, Flor A, Lisse TS, Przemeck GK, Horsch M, Schrewe A, Gailus-Durner V, Ivandic B, Katus HA, Wurst W, Reisenberg C, Chaney H, Fuchs H, Hans W, Beckers J, Marini JC, Hrabe de Angelis M (2012) Cardiopulmonary dysfunction in the osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms. Hum Mol Genet 21:3535–3545. https://doi.org/10.1093/hmg/dds183 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Scollan JP, Jauregui JJ, Jacobsen CM, Abzug JM (2017) The outcomes of nonelongating intramedullary fixation of the lower extremity for pediatric osteogenesis imperfecta patients: a meta-analysis. J Pediatr Orthop 37:e313–e316. https://doi.org/10.1097/BPO.0000000000000970 CrossRefPubMedGoogle Scholar
- 34.Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20:977–986. https://doi.org/10.1359/JBMR.050109 CrossRefPubMedGoogle Scholar
- 35.Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux FH, Rauch F (2015) Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years. J Bone Miner Res 30:2150–2157. https://doi.org/10.1002/jbmr.2567 CrossRefPubMedGoogle Scholar
- 36.Lindahl K, Kindmark A, Rubin CJ, Malmgren B, Grigelioniene G, Soderhall S, Ljunggren O, Astrom E (2016) Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with pamidronate. Bone 87:11–18. https://doi.org/10.1016/j.bone.2016.02.015 CrossRefPubMedGoogle Scholar
- 38.Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363:1427–1431. https://doi.org/10.1016/S0140-6736(04)16101-1 CrossRefPubMedGoogle Scholar